Envoy Medical, Inc., a prominent player in the health care sector, has recently announced a significant change in its independent registered public accounting firm. This development was disclosed in a current report filed on March 31, 2026. The company, which specializes in medical technologies for hearing loss, has elected Eisner Amper LLP to replace Grant Thornton LLP as its auditor for the fiscal year ending December 31, 2026.
Envoy Medical, Inc., headquartered in St. Paul, operates within the United States and is publicly traded on the Nasdaq stock exchange. The company’s mission is to revolutionize the hearing industry by meeting the needs of both providers and patients for suitable hearing devices. Despite its innovative approach, the company has faced financial challenges, as evidenced by its recent stock performance. As of March 30, 2026, the close price of Envoy Medical’s stock stood at $0.6651, a significant decline from its 52-week high of $1.91 on May 13, 2025. The stock reached a 52-week low of $0.363 on February 10, 2026. The company’s market capitalization is currently valued at $49,430,000 USD, and it reports a negative price-to-earnings ratio of -0.53.
The decision to switch auditors comes in the wake of Grant Thornton LLP’s recent audit opinions for the 2025 and 2024 financial statements. While these reports contained no adverse or qualified remarks, they did highlight significant doubt regarding Envoy Medical’s ability to continue as a going concern. This concern underscores the financial uncertainties facing the company. In response to the change, Envoy Medical provided Grant Thornton with the current filing and received a letter affirming the firm’s agreement with the report’s contents.
The transition to Eisner Amper LLP is a strategic move by Envoy Medical’s audit committee, aimed at ensuring robust financial oversight and addressing the concerns raised in previous audits. This change is part of the company’s broader efforts to stabilize its financial position and reinforce investor confidence. No other material corporate events or financial statement changes were reported in the filing, indicating that the primary focus remains on addressing the company’s financial health and operational challenges.
As Envoy Medical navigates these changes, stakeholders will be closely monitoring the company’s ability to implement effective strategies to overcome its financial hurdles and continue its mission of transforming the hearing industry. The company’s commitment to innovation and patient care remains steadfast, even as it seeks to strengthen its financial foundation and ensure long-term sustainability.
